Global Blood Therapeutics Inc (GBT)

NASDAQ
27.52
+0.42(+1.55%)
  • Volume:
    349,136
  • Bid/Ask:
    27.46/27.53
  • Day's Range:
    27.31 - 28.01
  • Type:Equity
  • Market:United States
  • ISIN:US37890U1088
  • CUSIP:00037890U108

GBT Overview

Prev. Close
27.1
Day's Range
27.31-28.01
Revenue
164.78M
Open
27.27
52 wk Range
25.48-64.49
EPS
-4.3
Volume
349,136
Market Cap
1.69B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,290,423
P/E Ratio
-
Beta
1.05
1-Year Change
-51.02%
Shares Outstanding
62,412,062
Next Earnings Date
Nov 11, 2021
What is your sentiment on Global Blood Therapeutics Inc?
or
Vote to see community's results!

Global Blood Therapeutics Inc News

Global Blood Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyBuySellStrong Sell
Technical IndicatorsStrong SellBuyStrong BuyStrong SellStrong Sell
SummarySellBuyStrong BuyStrong SellStrong Sell

Global Blood Therapeutics Inc Company Profile

Global Blood Therapeutics Inc Company Profile

Employees
389

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.

Read More
  • Its 8/3/21 and this stock is sbout to rocket after dropping for over a year straight. Trade of the year
    0
    • what's happening in after hours? any news?
      0
      • This a GO
        0
    • Worthless company?
      0
      • https://newsglobetoday.com/2020/05/11/huge-growth-potential-ahead-global-blood-therapeutics-inc-gbt-stock-and-graftech-international-ltd-eaf-stock/
        0
        • WOW GBT very successful sickle cell treatment
          0
          • 70 is optimistic, but maybe 60...
            1
            • At least $106
              1
          • Looks like $35 is the IPO price. Must give some wriggle room to institutional investors.
            1
            • Buy ... 70$ next year
              0
              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.